PACB Q1 Earnings Call: Cost Reductions and Clinical Adoption Offset Market Headwinds

Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced better-than-expected revenue in Q1 CY2025, but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% above analysts’ consensus estimates.

Is now the time to buy PACB? Find out in our full research report (it’s free).

StockStory’s Take

PacBio’s first quarter results were influenced by a challenging capital equipment environment, especially in the academic and research institute segment, where funding pressures led to a decline in instrument sales. CEO Christian Henry cited a notable shift as hospitals and clinics accounted for a larger share of new system placements, reflecting growing clinical adoption of PacBio’s HiFi sequencing technology. Consumables revenue, buoyed by steady usage and typical year-end purchasing in Japan, continued to grow, offsetting some of the weakness in instrument shipments. Henry highlighted that consumable demand from academic customers remained stable, suggesting more resilience in usage-driven spending versus capital purchases. The company also implemented restructuring measures to lower operating expenses and sharpen its focus on long-read sequencing platforms.

Looking forward, PacBio’s outlook is shaped by macroeconomic uncertainty, including newly implemented tariffs between the U.S. and China and proposed NIH budget reductions. Management adjusted the lower end of its revenue guidance to reflect these risks, noting that future changes in trade or academic funding could further affect results. CEO Christian Henry emphasized a strategic focus on long-read technology and clinical applications, stating, “We are prioritizing our HiFi technology and the long-read sequencing market.” The company expects continued growth in clinical and diagnostic markets, expansion of the Vega platform, and further cost efficiencies from recent restructuring. CFO Jim Gibson added that PacBio aims to achieve positive cash flow by the end of 2027, with ongoing efforts to reduce cash burn and improve gross margins through innovation and operational discipline.

Key Insights from Management’s Remarks

Management attributed quarterly performance to resilient consumable sales, hospital and clinic adoption, and cost-cutting efforts, while acknowledging instrument headwinds from funding constraints and trade disruptions.

• Clinical customer momentum: PacBio saw increased system placements among hospital and clinic customers, with institutions like Lilly Children's Hospital and Imagine Institute leveraging HiFi sequencing for genetic disease testing—highlighting a shift from traditional academic buyers to clinical demand.
• Consumables drive revenue stability: Despite lower instrument sales, consumable revenues grew 26% year-over-year, supported by steady utilization of the Revio installed base and year-end purchasing in Japan. Management noted that consumable demand from academic customers remained stable, even as capital spending declined.
• Restructuring to cut costs: The company initiated a restructuring plan in April to narrow its strategic focus and reduce annualized non-GAAP operating expenses by $45–$50 million. This included headcount reductions and prioritizing long-read platform development, aiming to extend cash runway and improve margins.
• Vega platform broadens reach: The newly launched Vega benchtop sequencer is expanding PacBio’s customer base, with approximately half of Q1 shipments to new customers. Vega’s lower capital cost and ease of use have made it attractive in a constrained funding environment.
• Product innovation and partnerships: The ongoing rollout of Spark chemistry for the Revio platform and licensing agreements for advanced methylation analysis are intended to improve sequencing performance and open new research applications, enhancing PacBio’s competitive position.

Drivers of Future Performance

PacBio’s full-year outlook is primarily driven by clinical market expansion, new product launches, and the impact of global funding and trade policy uncertainties.

• Clinical adoption and diversification: Management expects continued growth in hospital and clinical accounts to offset ongoing weakness in academic funding. Expansion of kitted solutions like PureTarget for diagnostic labs is a priority, with the aim of generating more durable, recurring revenue streams.
• Operational efficiency and restructuring: The recent cost reduction program is projected to lower non-GAAP operating expenses and improve gross margins, with further benefits anticipated in 2026. Management believes these measures are critical for achieving cash flow positivity by 2027, especially amid uncertain macro conditions.
• Trade and funding risks: PacBio’s guidance reflects potential disruptions from U.S.-China tariffs and proposed NIH budget cuts. Management indicated that further deterioration in trade or funding could impact instrument shipments, particularly in China and U.S. academic markets. Upside scenarios include increased clinical placements and higher consumable utilization.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace of clinical and hospital-based system placements, (2) the impact of tariffs and funding changes on instrument shipments—particularly in China and U.S. academic markets, and (3) the continued ramp of Vega production and its pull-through on consumables. Execution on product innovation and realization of restructuring savings will also be critical milestones.

PacBio currently trades at a forward price-to-sales ratio of 2.2×. Should you double down or take your chips? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.